

« Non quia difficilia sunt non audemus, sed quia non audemus difficilia sunt. »

(Ce n'est pas parce que les choses sont difficiles que nous n'osons pas, c'est parce que nous n'osons pas qu'elles sont difficiles.)

- Seneca

Table of contents

PART ONE	5
Abbreviations	7
Summary	9
Résumé	10
Introduction	13
Chronic lung allograft dysfunction	13
Bronchiolitis obliterans syndrome (BOS)	16
Diagnosis of BOS	16
BOS Pathology	16
Immune responses and chronic repair processes in BOS development	18
Risk factors for BOS development	20
Restrictive allograft dysfunction (RAS)	23
Treatments in lung transplanted patients	25
Induction therapy	25
Maintenance therapy	26
Salvage treatments for progressive BOS	31
Anti-fibrotic drugs	33
Animal models of BOS	34
Heterotopic tracheal transplantation	34
Orthotopic lung transplantation	37
Organ fibrosis	41
The myofibroblast at the heart of organ fibrosis	44
Donor or recipient? The controversial origin of fibrosis in BOS	54
Aim of the work	57
Summary of experimental results	59
Discussion	65
Recipient-derived mesenchymal cells in post-transplant airway fibrosis	65
Tacrolimus effects on airways fibrogenesis	65
Epithelial-to-mesenchymal transition only occurs under reduced alloreactivity	66
The mononuclear phagocyte system as a major source for mesenchymal cells	68
The thin line between fibrocytes and pro-fibrotic macrophages	69
Shared genetic signatures between obliterative airway disease and idiopathic pulmonary fibrosis	70
The enigmatic myofibroblast: one marker, one function...multiple cells?	72
Limitations of the study	73

Targeting the mononuclear phagocyte system	76
The Cx3cl1/Cx3cR1 axis	76
Monocyte-to-fibrocyte transition and fibrocytes activation	77
Systems approach, endotypes and tailored treatments	78
Conclusions	79
References	80
Supplementary Information	109
PART TWO: Original article	113
The mononuclear phagocyte system contributes to fibrosis in post-transplant Obliterans Bronchiolitis	115
Abstract	116
Introduction	117
Results	118
<i>Myofibroblasts in post-transplant obliterative lesions are recipient-derived.</i>	118
<i>Tacrolimus treatment reduces post-transplant obliterative lesions and allows the survival of donor-derived myofibroblasts in the allografts.</i>	118
<i>Cells from the myeloid lineage give rise to the majority of myofibroblasts found in obliterative airways fibrosis.</i>	119
<i>The mononuclear phagocyte system represents a potential source of myofibroblasts.</i>	120
<i>Cx3cR1-lineage cells express mesenchymal marker αSMA and synthesize pro-Collagen I...</i> 122	
<i>Ablation of Cx3cR1⁺ cells decreases fibrotic occlusion and myofibroblasts accumulation in the allografts.</i>	122
<i>CD68⁺ myofibroblasts are detected in fibrotic lesions from human BOS explants.</i>	123
Discussion.....	124
Methods	126
References	128
Figures	135
Supplementary data	148
Supplementary figures	149
Extended methods	157
Remerciements / Ringraziamenti	167